A class action filed in New Jersey alleges ADMA Biologics inflated its 2025 revenue through channel stuffing and an undisclosed related-party distributor tied to its own vice chairman. In two trading days, the stock lost twenty-nine percent.
A securities class action says Embecta executives told investors the insulin pen franchise was "incredibly resolute" while the numbers underneath were already breaking. On May 5, 2026, the stock collapsed 57.8 percent in a single trading day.
A short seller said ADMA's 20% growth was really a 3% decline hidden in distributor warehouses. The stock fell 29% in two days. Now the lawsuits are stacking up.
A Boston jury found Takeda liable for paying a generic rival to stay off the market, delaying a cheaper version of Amitiza by roughly six years. The single-damages number is $885 million. Antitrust law triples it.
Between February 2025 and February 2026, Pinterest management told investors the platform could handle whatever the economy threw at it. The complaint alleges the economy threw exactly what management already knew was coming, and management kept talking anyway.